TScan announced the start of trials for a cancer antigen

5月14日

Biotechnology company TScan Therapeutics Inc. announced last week that the first patient in the phase 1 clinical trial had been dosed with its new TCR-T therapy to treat solid tumours. TScan Therapeutics will soon provide data on the progress of its TCR-T experiments, which could attract investor attention.

The commencement of clinical trials marks a significant milestone for TScan Therapeutics, a company that has strategically positioned itself in the high-demand melanoma treatment market. With preparations underway for three patients and plans to expand its subject pool, TScan Therapeutics is demonstrating its proactive approach to potential growth.

Let's delve into the technical analysis of TScan Therapeutics Inc (NASDAQ: TCRX) to explore investment opportunities.

On the Daily (D1) timeframe, resistance has been identified at 8.80 USD and support at 7.05 USD. Following the recent correction, the stock has started an upward trend, suggesting the potential for further growth and breaking new historical highs.

In a trend reversal, the stock's decline target may be 4.65 USD.

If the upward trend continues and the resistance level at 8.80 USD is broken, the stock has the potential to reach 12.40 USD. Taking a medium-term outlook, the analysis suggests a rise to 14.45 USD.
—
Ideas and other content presented on this page should not be considered as guidance for trading or an investment advice. RoboMarkets bears no responsibility for trading results based on trading opinions described in these analytical reviews.

The material presented and the information contained herein is for information purposes only and in no way should be considered as the provision of investment advice for the purposes of Investment Firms Law L. 87(I)/2017 of the Republic of Cyprus or any other form of personal advice or recommendation, which relates to certain types of transactions with certain types of financial instruments.

Risk Warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69.88% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.